BETR BetterLife Pharma Inc.
Debt Financing ·
BetterLife Pharma closed a CAD $2,000,000 convertible debenture on June 22, 2026, and a director and insider subscribed for the full amount. The conversion price compares with $0.07 per unit in an April 2026 private placement.
We have not published a story on BetterLife Pharma yet. When there is news, it will appear here.
BetterLife Pharma Inc. is a biopharmaceutical company, incorporated in British Columbia, Canada, that is engaged in the development of patented pharmaceuticals. Its lead program, BETR-001, is a non-hallucinogenic second-generation LSD derivative, 2-bromo-LSD, that the company plans to develop for major depressive disorder, anxiety disorder, neuropathic pain and other neuro-psychiatric and neurological disorders. The company says BETR-001 is at the preclinical stage, with GMP manufacturing of oral capsules being completed. Its subsidiary MedMelior Inc. has two pipeline products: MM-001, a topical formulation of recombinant human IFNa2b for cervical intraepithelial neoplasia, and MM-003, a patent pending inhalation formulation of interferon alpha-2b. The company intends to use contract development and manufacturing organizations on a fee for service basis. Its stated goal is to develop BETR-001 as a patient self-administered medication prescribed by a psychiatrist.
| Product or program | What it is | Stage |
|---|---|---|
| BETR-001 | Non-hallucinogenic 2-bromo-LSD derivative for depression, anxiety and neuropathic pain | preclinical |
| MM-001 | Topical IFNa2b cream for HPV-induced cervical intraepithelial neoplasia | clinical stage; Phase 1-2 trials completed |
| MM-003 | Patent pending inhalation formulation of interferon alpha-2b | preclinical |
Our latest story on this, dated Jun 22, 2026: "BetterLife closes CAD $2,000,000 convertible debenture financing". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 22, 2026: "BetterLife closes CAD $2,000,000 convertible debenture financing". The story links the filing or release it is based on. Read the story.
BetterLife Pharma Inc. trades under the ticker BETR on CSE.
BetterLife Pharma Inc. is listed on CSE. Our directory also records these other listings: GETTEX:NPAU; LS:A2P7XN; LSX:A2P7XN; NEO:BETR; OTC:BETRF.
The SEC Central Index Key (CIK) for BetterLife Pharma Inc. is 1464165. Its filings are on SEC EDGAR.
145,494,883 shares as of 2025-05-30, per the cover page of its 20-F filed 2025-06-02.
Our directory records BetterLife Pharma Inc. under Canada.
Our directory classifies BetterLife Pharma Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for BetterLife Pharma Inc. is CA08772P2026.
aibio.space lists BetterLife Pharma Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as A1.
BetterLife Pharma Inc. is a biopharmaceutical company, incorporated in British Columbia, Canada, that is engaged in the development of patented pharmaceuticals. Its lead program, BETR-001, is a non-hallucinogenic second-generation LSD derivative, 2-bromo-LSD, that the company plans to develop for major depressive disorder, anxiety disorder, neuropathic pain and other neuro-psychiatric and neurological disorders.
BETR-001: Non-hallucinogenic 2-bromo-LSD derivative for depression, anxiety and neuropathic pain Stage: preclinical.
MM-001: Topical IFNa2b cream for HPV-induced cervical intraepithelial neoplasia Stage: clinical stage; Phase 1-2 trials completed.
BetterLife Pharma Inc. reported a net loss of $121,182 for the fiscal year ended Jan 31, 2018, and used $395,602 of cash in operations, per its annual report to the SEC.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio